Tredje AP fonden Has $791,000 Position in Exact Sciences Co. (NASDAQ:EXAS)

Tredje AP fonden trimmed its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 50.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,080 shares of the medical research company’s stock after selling 14,080 shares during the quarter. Tredje AP fonden’s holdings in Exact Sciences were worth $791,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Perigon Wealth Management LLC lifted its stake in Exact Sciences by 3.2% in the fourth quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company’s stock valued at $474,000 after buying an additional 264 shares during the period. Sanctuary Advisors LLC lifted its position in shares of Exact Sciences by 2.0% during the 4th quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company’s stock valued at $763,000 after acquiring an additional 269 shares during the period. Daiwa Securities Group Inc. boosted its stake in Exact Sciences by 2.1% during the fourth quarter. Daiwa Securities Group Inc. now owns 14,447 shares of the medical research company’s stock worth $812,000 after acquiring an additional 300 shares in the last quarter. Huntington National Bank grew its holdings in Exact Sciences by 838.1% in the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after purchasing an additional 352 shares during the period. Finally, CIBC Asset Management Inc increased its stake in Exact Sciences by 6.1% in the third quarter. CIBC Asset Management Inc now owns 6,489 shares of the medical research company’s stock valued at $442,000 after purchasing an additional 371 shares in the last quarter. Institutional investors own 88.82% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on EXAS shares. Piper Sandler cut their price objective on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. TD Cowen raised their price objective on Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. BTIG Research increased their target price on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. William Blair restated an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 20th. Finally, Scotiabank boosted their target price on shares of Exact Sciences from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a research report on Monday, February 24th. Two investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $70.83.

Exact Sciences Stock Performance

Shares of EXAS stock opened at $45.00 on Friday. Exact Sciences Co. has a 52 week low of $40.62 and a 52 week high of $79.62. The firm’s 50-day simple moving average is $51.73 and its two-hundred day simple moving average is $58.84. The firm has a market cap of $8.36 billion, a price-to-earnings ratio of -8.08 and a beta of 1.25. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million. As a group, equities analysts forecast that Exact Sciences Co. will post -0.58 earnings per share for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.